LANSING, Mich., May 30, 2023 /PRNewswire/ -- Neogen® Corporation (NASDAQ: NEOG) announced today that the Company will participate in the 43rd Annual William Blair Growth Stock Conference in Chicago, Illinois, on Tuesday, June 6, 2023.
John Adent, Neogen's President and Chief Executive Officer, will present at 4:00 p.m. Central Time.
Presentation materials will be posted to the Neogen Investor Relations website on the morning of June 6. To access them, along with the event webcast link, please visit the Events & Presentations section at neogen.com/investor-relations/events-presentations.
About Neogen
Neogen Corporation develops and markets comprehensive solutions dedicated to food and animal safety, operating with the intention to "Every day, protect the people and animals we care about." The Company's Food Safety segment markets dehydrated culture media and diagnostic test kits to detect foodborne bacteria, natural toxins, food allergens, drug residues, plant diseases, and sanitation concerns. Neogen's Animal Safety segment is a leader in the development of genomic solutions along with the manufacturing and distribution of a variety of animal healthcare products, including diagnostics, pharmaceuticals, veterinary instruments, wound care, and disinfectants, as well as rodent and insect control solutions.
CONTACT: | Bill Waelke, Investor Relations |
517.372.9200, This email address is being protected from spambots. You need JavaScript enabled to view it. |
| Last Trade: | US$5.64 |
| Daily Change: | -0.11 -1.91 |
| Daily Volume: | 3,153,960 |
| Market Cap: | US$1.230B |
May 13, 2025 January 21, 2025 January 10, 2025 December 17, 2024 | |
C4 Therapeutics is pioneering a new class of small-molecule drugs that selectively destroy disease-causing proteins via degradation using the innate machinery of the cell. This targeted protein degradation approach offers advantages over traditional drugs, including the potential to treat a wider range of diseases...
CLICK TO LEARN MORE
Chimerix is on a mission to develop medicines that meaningfully improve and extend the lives of patients facing deadly diseases. The company is devoted to filling gaps in the treatment paradigm. Chimerix’s most advanced clinical-stage program is in development for H3 K27M-mutant glioma....
CLICK TO LEARN MORE
